收藏切换
A preliminary analysis of WHO's initiatives and tools for promoting the improvement of medical product regulatory capacity worldwide (part Ⅱ): key requirements for the global benchmarking tool and the WHO-listed authorities framework
收藏切换
Yan-ling ZHANG1, 2, Ming-shu MA2, Yi-fei WANG2, Rong SHAO1, *
Chinese Journal of New Drugs | 2026, 35(9) : 924 - 931
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(9): 924-931
A preliminary analysis of WHO's initiatives and tools for promoting the improvement of medical product regulatory capacity worldwide (part Ⅱ): key requirements for the global benchmarking tool and the WHO-listed authorities framework
Full
Yan-ling ZHANG1, 2, Ming-shu MA2, Yi-fei WANG2, Rong SHAO1, *
Affiliations
  • 1School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China
  • 2Health China Research Institute, China Health Media Group, Beijing 100082, China
Published: 2026-05-15 doi: 10.20251/j.cnki.1003-3734.2026.09.005
Outline
收藏切换

The WHO launched the regulatory system strengthening program for medical products in 2014, aiming to encourage the enhancement of medical product regulatory levels in countries and promote the coordinated development of regulatory capabilities globally. This initiative encompasses guidelines on quality management systems, good regulatory practices, good trust practices, and a global regulatory capacity framework. Its core tools are the global benchmarking tool (GBT) for regulatory system assessment and the WHO-listed authorities (WLA) framework built upon the GBT. Understanding the assessment requirements of the GBT and WLA can not only provide ideas for improving China's drug regulatory system but also serve as a reference for aligning regulatory work with international standards. This paper systematically introduces the assessment dimensions and key requirements of the GBT and WLA in order to explore their intrinsic relationship with relevant guiding principles.

WHO  /  regulatory systems strengthening  /  global benchmarking tool  /  WHO-listed authorities  /  performance evaluation
张燕玲, 马茗舒, 王艺霏, 邵蓉. 浅析WHO促进各国医疗产品监管水平提升的举措与工具(下)——全球基准评估工具和WHO列名机构框架的关键要求. 中国新药杂志, 2026 , 35 (9) : 924 -931 . DOI: 10.20251/j.cnki.1003-3734.2026.09.005
Yan-ling ZHANG, Ming-shu MA, Yi-fei WANG, Rong SHAO. A preliminary analysis of WHO's initiatives and tools for promoting the improvement of medical product regulatory capacity worldwide (part Ⅱ): key requirements for the global benchmarking tool and the WHO-listed authorities framework[J]. Chinese Journal of New Drugs, 2026 , 35 (9) : 924 -931 . DOI: 10.20251/j.cnki.1003-3734.2026.09.005
Year 2026 volume 35 Issue 9
42
8
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.09.005
  • Online Date:2026-10-26
  • Published:2026-05-15
Article Data
Affiliations
History
  • Accepted:2026-01-12
Affiliations
    1School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China
    2Health China Research Institute, China Health Media Group, Beijing 100082, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.09.005
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT